India's Pharmaceutical Sector Growth and Future Path

#GS-3 #Economy #Infrastructure #Science & Technology #Health #Current Events #National

Why in News

The Union Minister of Commerce and Industry invited international pharma firms to invest in the healthcare sector of India.
The current market value of the $60 billion industry can double over the next five years.

The global community recognizes India as the Pharmacy of the World for public health support.
The sector manufactures affordable generic drugs, vaccines, APIs, and complex biosimilars.

The Indian pharmaceutical market is valued at $60 billion in the year 2026.
India supplies roughly 65% to 70% of the global vaccine needs for the WHO.
The country hosts 10 of the world's 25 largest generic drug makers.
India holds the highest number of US FDA approved manufacturing plants outside the United States.
Pharmaceutical exports grew from $15.07 billion in 2013-14 to $27.85 billion recently.

Traditional small molecule drugs account for a dominant 76% share of market revenue.
Biologics and biosimilars form the fastest-growing sector with an estimated 15.8% CAGR.
Cardiovascular categories hold a 14.6% market share as chronic therapies expand rapidly.
Brick-and-mortar retail pharmacies handle 64.57% of all domestic medicine sales.
West India, featuring Gujarat and Maharashtra, retains a 32.24% share of total market output.

India imports roughly $4.35 billion worth of bulk drugs and intermediates annually.
A single country accounts for 73.7% of these raw material imports.
Indian firms invest only 7% to 8% of revenues into core R&D compared to global levels.
Compliance upgrades and site cleaning cost $6 million to $18 million per facility.
Strict domestic price controls and global competition create intense profit pressures.

Public and private funding must coordinate to shift focus toward advanced specialty biologics.
The bulk drug PLI Scheme should expand to reduce dependency on imported starting materials.
The Biopharma Shakti initiative and a $10 billion R&D fund will provide high-risk capital.
The revised Schedule M guidelines will align domestic factories with international GMP standards.
Advanced artificial intelligence tools can automate digital audits and lower operational costs.